卡马替尼

卡马替尼（CAS 1029712-80-8）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

In the US, capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Capmatinib is approved to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations in Canada.Capmatinib is an orally available, small molecule inhibitor of the mesenchymal-epithelial transition (MET) factor tyrosine kinase receptor that is used in selected patients with non-small cell lung cancer (NSCLC). Serum aminotransferase elevations are common during therapy with capmatinib, which rarely can lead to clinically apparent liver injury that can be severe and even fatal.

同义词与商品名

capmatinib; 1029712-80-8; INCB28060; INC-280; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INCB-28060; NVP-INC280-NX; INCB 28060; NVP-INC280; TY34L4F9OZ; 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; INCB-28060 FREE BASE; DTXSID90145595; 2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide; capmatinibum

GHS 危害分类

Reported hazard statements	H301 (100%), H360 (25%), H373 (100%), H411 (100%)

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

H360 (25%): May damage fertility or the unborn child [Danger Reproductive toxicity]

公开数据库对它的描述

Capmatinib · CAS 1029712-80-8 · C23H17FN6O. UNII TY34L4F9OZ.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。